Harpoon Therapeutics is a clinical-stage immunotherapy company that develops a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. View on: LinkedIn.com | Sales Navigator.

New Funding Raised: $150M, Post-IPO Equity

Round Investors: K2 HealthVentures, Invus, Soleus Capital, Ally Bridge Group

🚀Growth Focus: Develop programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328.

Press: GlobeNewswire, Harpoon Therapeutics

HQ: San Francisco, CA

Industry: Pharmaceutical Manufacturing

Employee Count: 53